Pasithea Therapeutics Corp. (KTTA) Executive Compensation
Pasithea Therapeutics Corp. (KTTA) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: KTTA
CIK: 1841330
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
CBIZ CPAs P.C.
Auditor SinceSince 12/31/2025 12:00:00 AM
Lead Engagement PartnerKevin Burkhardt
Audit LocationHartford, Connecticut, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-09-16 | 2026-09-16 | CURRENT REPORT | 0001213900-26-100515 | View SEC Doc Filr Page |
| 25-NSE | 2026-09-16 | — | 25-NSE Filing | 0001354457-26-000883 | View SEC Doc Filr Page |
| 8-K | 2026-09-09 | 2026-09-09 | CURRENT REPORT | 0001213900-26-098405 | View SEC Doc Filr Page |
| 8-K | 2026-08-21 | 2026-08-20 | CURRENT REPORT | 0001213900-26-092672 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-090146 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-08-14 | — | SCHEDULE 13G/A Filing | 0001213900-26-090016 | View SEC Doc Filr Page |
| ARS | 2026-08-07 | 2025-12-31 | FORM ARS | 0001213900-26-086803 | View SEC Doc Filr Page |
| DEF 14A | 2026-08-07 | 2026-09-09 | DEFINITIVE PROXY STATEMENT | 0001213900-26-086799 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-31 | — | SCHEDULE 13G/A Filing | 0001493152-26-035625 | View SEC Doc Filr Page |
| PRE 14A | 2026-07-29 | 2026-07-29 | PRELIMINARY PROXY STATEMENT | 0001213900-26-082894 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-07-01 | — | SCHEDULE 13G/A Filing | 0001104659-26-079982 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-06-23 | — | SCHEDULE 13G Filing | 0001440771-26-000010 | View SEC Doc Filr Page |
| 4 | 2026-06-22 | 2026-06-17 | OWNERSHIP DOCUMENT | 0001104659-26-076184 | View SEC Doc Filr Page |
| 10-Q | 2026-05-15 | 2026-03-31 | QUARTERLY REPORT | 0001213900-26-057837 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0001193125-26-225634 | View SEC Doc Filr Page |
| 4 | 2026-05-05 | 2026-05-01 | 4 Filing | 0001213900-26-052262 | View SEC Doc Filr Page |
| 4 | 2026-05-05 | 2026-05-01 | 4 Filing | 0001213900-26-052261 | View SEC Doc Filr Page |
| 4 | 2026-05-05 | 2026-05-01 | 4 Filing | 0001213900-26-052260 | View SEC Doc Filr Page |
| 4 | 2026-05-05 | 2026-05-01 | 4 Filing | 0001213900-26-052259 | View SEC Doc Filr Page |
| 4 | 2026-05-05 | 2026-05-01 | 4 Filing | 0001213900-26-052258 | View SEC Doc Filr Page |
| 4 | 2026-05-05 | 2026-05-01 | 4 Filing | 0001213900-26-052257 | View SEC Doc Filr Page |
| 4 | 2026-05-05 | 2026-05-01 | 4 Filing | 0001213900-26-052256 | View SEC Doc Filr Page |
| 3 | 2026-05-05 | 2026-05-01 | 3 Filing | 0001213900-26-052254 | View SEC Doc Filr Page |
| 8-K | 2026-05-04 | 2026-05-01 | CURRENT REPORT | 0001213900-26-051681 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-04-22 | — | SCHEDULE 13G Filing | 0002073679-26-000048 | View SEC Doc Filr Page |